The visceral adiposity index (VAI) has proved to be a marker of visceral adipose dysfunction, strongly associated with insulin sensitivity in both the general and specific populations of patients at metabolic risk.
and increased FFA flux from adipose to peripheral tissues (3) . In acromegaly, the lipolytic and insulin-antagonistic effects of GH may alter adipose tissue distribution. Increasing GH/IGF-I levels are associated with a smaller proportion of total adipose tissue, and a negative correlation between insulin sensitivity and sc, im, and total adipose tissue was detected (4) . Recently, we proposed a sex-specific mathematical index, the visceral adiposity index (VAI), based on simple anthropometric and metabolic parameters, as a surrogate marker of adipose tissue function and distribution independently correlated with cardiometabolic risk in the general population (5) . VAI showed a strong association with both insulin sensitivity (evaluated with a euglycemic-hyperinsulinemic clamp) and visceral adipose tissue [measured with magnetic resonance imaging (MRI)] (5). Furthermore, circulating concentrations of inflammatory adipocytokines are recognized to be the most important factor in causing and maintaining insulin resistance (IR) as well as a rise in FFA levels (6) . In our hypothesis, insulin sensitivity, lipolytic activity, and adipocytokine production, which play a main role in the genesis of cardiovascular sequelae in the general population (7) (8) (9) , may be indirectly represented by VAI. The aim of this study was to test VAI as a useful new tool to assess early metabolic risk in patients with active acromegaly and to evaluate its association with adipocytokine levels and insulin sensitivity and secretion parameters.
Patients and Methods
For the purpose of the study, we enrolled 24 patients (13 males and 11 females; aged 54.9 Ϯ 13.6 yr, range 33-78 yr) with active newly diagnosed acromegaly, who presented at the Endocrinology Section of the University of Palermo from January 1, 2004 , to December 31, 2011 . Patients with mixed GH/prolactin-secreting adenoma, previously treated with acromegaly therapy (surgery, somatostatin analogs, dopamine agonist, or pegvisomant) or with deficiency of one or more anterior pituitary hormones were excluded from this study. Activity of disease at the time of the study was confirmed by plasma mean GH profile, elevated age-and gender-corrected plasma IGF-I levels, and nonsuppressible GH after an oral glucose tolerance test (OGTT) (10) . In all patients, MRI scan revealed the presence of a pituitary tumor. Tumor volume was calculated in line with the Di Chiro and Nelson formula (volume ϭ height ϫ length ϫ width ϫ /6) and was expressed as cubic millimeters. The mean duration of the disease was established by patient interview, patient clinical pictures, and onset of osteoarticular symptoms. At the time of hospitalization, all patients signed a consent form for the scientific use of their data after a full explanation of the purpose of the study. This study was approved by the Institutional Review Board of the Faculty of Medicine, University of Palermo, and the identity of the participants remained anonymous during database analysis.
Study design
Body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were measured in all patients. WC was measured at the midpoint between the lower rib and the iliac crest. After an overnight fast, lipid profile [total, high-density lipoprotein (HDL), and lowdensity lipoprotein (LDL) cholesterol and triglycerides (TG)], hemoglobin A1c (HbA1c), mean fasting plasma GH (at least three blood samples at 30-min intervals), and IGF-I levels were measured. To normalize IGF-I for age in individual patients, we calculated the ratio between the IGF-I level and the upper limit of the normal (ULN) range for age (normal Յ 1), and the data are presented as IGF-I ULN. OGTT was performed by measuring plasma blood glucose, insulin, and GH levels every 30 min for 2 h after a 75-g oral glucose load, and the area under the curve (AUC) of GH (AUC GH ) was calculated. Insulin sensitivity was tested with the euglycemic-hyperinsulinemic clamp (11) . The clamp was performed under standard conditions, i.e. infusion of an insulin priming of 160 mU/m 2 body surface for the first 4 min of the test, followed by 40 mU/m 2 for the remaining 116 min; the rate of peripheral glucose utilization (M value) was calculated by dividing the glucose amount infused during the last 40 min by body weight measured in kilograms (milligrams per kilogram per minute). Under the steady-state conditions of euglycemia, the glucose infusion rate equals glucose uptake by all the tissues in the body and is therefore a measure of tissue sensitivity to exogenous insulin. ␤-Cell function was accurately and directly determined by measuring serum C-peptide levels before and after the standard mixed-meal tolerance test (MMTT) (12) . A liquid meal (6 mg/kg up to a maximum of 360 ml) of Ensure Plus (25 g protein, 80.8 g carbohydrate, 20.6 g fat) was given after a 12-to 14-h overnight fast. Blood was drawn every 30 min for 120 min during the MMTT for the determination of glucose and C-peptide levels, and the AUC of C-peptide (AUC Cpeptide ) was calculated. In addition, ␤-cell function relative to insulin sensitivity, assessed by oral disposition index (DIo) (13) , was evaluated.
To avoid significant gaps in time between the various tests, we routinely applied to all subjects our internal protocol of management of newly diagnosed acromegalic patients, which performs the OGTT during first access (baseline). If the diagnosis of acromegaly is confirmed, we plan the euglycemic-hyperinsulinemic clamp 1 wk after the baseline and the MMTT 2 wk after the baseline. VAI was calculated as described (5) According to specific age-stratified cutoff points of VAI identifying patients with presumed visceral adipose dysfunction and cardiometabolic risk (14) , we divided the patients into two groups: those with normal (group A, 13 patients) and those with high VAI (group B, 11 patients). The appropriate cutoff points of VAI used were the following: 2.52 for subjects under 30 yr, 2.23 for those aged between 30 and 42 yr, 1.92 between 42 and 52 yr, 1.93 between 52 and 66 yr, and 2.00 for subjects over 66 yr. In addition, to obtain better evaluation of adipose function, in all patients we measured serum levels of four circulating adipocytokines: leptin, adiponectin, IL-6, and TNF-␣. All samples (for glycemia, HbA1c, lipid profile, insulin, C-peptide, GH, and IGF-I) were immediately analyzed after the tests were performed in each individual after an overnight fast. Serum samples to be used for the adipocytokine determinations were kept frozen at Ϫ20 C until assayed at the end of the study.
Patients with a previous diagnosis of diabetes mellitus, already treated, were excluded from this study to avoid the impact of the treatment on metabolic parameters and because of their inability to perform the OGTT. At the time of the study, patients diagnosed after the OGTT as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) were treated with a controlled diet only after the completion of the study design to avoid the impact of strict adherence to diet on the results of the study and to evaluate the main role of GH on metabolic parameters. No patients with previous diagnosis of IFG or IGT recruited in the study were already receiving dietary or pharmacological treatment.
Among the patients affected by increased blood pressure, those with a previous diagnosis of hypertension (70%) received pharmacological treatment with sartans (58%) or angiotensinconverting-enzyme inhibitors (42%). The patients diagnosed as having systolic or diastolic hypertension for the first time at the time of the diagnosis of acromegaly did not receive any specific treatment until the end of the study design period (2 wk), during which they underwent intensive blood pressure control.
Among the dyslipidemic patients, those with a previous diagnosis (43%) had never received specific treatment. We first diagnosed dyslipidemia in four patients who had never received any dietary or pharmacological treatment until the end of the study protocol to avoid the impact of the treatment on metabolic parameters.
Hormone and biochemical assays
All biochemical data were collected after overnight fasting. Glycemia, HbA1c, and lipid levels were measured in our centralized accredited laboratory with standard methods. During the entire study period, GH samples from all subjects were run in the same immunoradiometric assay (Radium, Pomezia, Italy). The sensitivity of the assays was 0.05 g/liter. The average intraand interassay coefficients of variation (CV) were 4.5 and 7.9%, respectively. Serum IGF-I was measured using immunoradiometric assays (Diagnostic System Laboratories Inc., Webster, TX). The normal ranges (for age) were 180 -625 and 151-530 (Յ20), 118 -475 and 118 -450 (21-30), 102-400 and 100 -390 (31-40), 100 -306 and 96 -228 (41-50), 95-270 and 90 -250 (51-60), 88 -250 and 82-200 (61-70), and 78 -200 and 68 -188 (Ն70) g/liter for men and women, respectively. The sensitivity of the assay was 0.8 g/liter. The intra-and interassay CV were 3.4, 3.0, and 1.5% and 8.2, 1.5, and 3.7% for low, medium, and high points on the standard curve, respectively. Serum insulin was measured by ELISA (DRG Instruments GmbH, Marburg, Germany). The sensitivity of the method was 1 IU/ml. The normal insulin range was 5-19 IU/ml. Serum Cpeptide was measured by ELISA (DRG Instruments). The sensitivity of the method was 0.064 ng/ml. The intra-and interassay CV were 5.1-6.7% and 8.3-9.9%, respectively. The assays for the assessment of IGF-I, insulin, and C-peptide were constant during the entire period of the study. Circulating leptin and adiponectin were measured using ELISA kits from SPI bio (Montigny le Bretonneux, France). For leptin, the limit of sensitivity was 0.5 ng/ml, and the intra-and interassay CV were 3.0 -7.5 and 3.2-9.2% at leptin levels of 3.5-25.5 and 5.4 -25.1 ng/ml, respectively. For adiponectin, the limit of sensitivity was 0.7 g/ ml, and the intra-and interassay CV were 6.4 -7.0 and 7.3-8.2% at adiponectin levels of 7.1-21.1 and 5.2-17.7 g/ml, respectively. TNF-␣ was measured by ELISA (Amersham human TNF-␣, Biotrak Easy ELISA; GE Healthcare, Piscataway, NJ). The sensitivity of the method was 2.5 pg/ml. The overall intraand interassay CV were 6.0 and 9.3%, respectively. IL-6 was measured by ELISA (human IL-6 ultrasensitive; Invitrogen, Camarillo, CA). The sensitivity of the method was less than 104 fg/ml. The intra-and interassay CV were 4.7-8.3 and 6.7-10%, respectively.
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17 was used for data analysis. Baseline characteristics were presented as mean Ϯ SD or as median and interquartile range for continuous variables; rates and proportions were calculated for categorical data. The normality of distribution of the quantitative variables was assessed by means of the Kolmogorov-Smirnov test). The differences between the two groups of patients (with normal or high VAI) were evaluated with the Mann-Whitney U test. Simple univariate correlations among continuous variables without normal distribution were determined by Spearman's test, the nonparametric equivalent for Pearson's test. To evaluate the independent variables influencing the VAI in all acromegalic patients, a linear regression model was performed. A P value Ͻ0.05 was considered statistically significant.
Results
The clinical and biochemical features of patients are shown in Table 1 .
In the entire cohort of patients, the mean VAI value was 1.9 Ϯ 0.8. Thirteen patients (54.2%) were classified as having normal VAI (group A), whereas 11 (45.8%) had high VAI (group B). No age, gender, or BMI difference was found between the two groups. Group B showed significantly higher basal GH [32 (3.10 -36) 16) ; P ϭ 0.047] than group A, whereas no difference was found in nadir GH, tumor size, and duration of disease. Group B also showed a higher prevalence of family history for diabetes (10 vs. 4%; P ϭ 0.005) ( Table 2) .
Using the National Cholesterol Education Program Adult Treatment Panel III criteria (15) , in the whole cohort of patients, the metabolic syndrome (MS) was found in six patients (25%). Specifically, 17 patients (70.8%) had systolic hypertension, 13 (54.2%) had diastolic hypertension, seven (29.2%) were affected by hypertriglyceridemia, 10 (41.7%) showed increased WC, and seven (29.2%) had low HDL-cholesterol levels ( Table 1) . No difference in MS as a whole and in each of its components was reported between the two groups, with the exception of the prevalence of systolic hypertension, which was significantly higher in group B (11 vs. 6%; P ϭ 0.006) ( Table 2) .
Six of 24 patients (25%) were classified as having normal glucose tolerance, 11 (45.8%) IFG, and seven (29.2%) IGT. No patient had overt diabetes mellitus, according to the medical guidelines of the American Association of Clinical Endocrinologists (16) ( Table 1) . No difference in each category of glucose tolerance was found between the two groups, with the exception of a significantly higher prevalence of IGT in group B (P ϭ 0.001).
No difference between the two groups of patients was found in fasting glucose and HbA1c levels. 10 .50 (9.10 -15.95) g/ml; P Ͻ 0.001] than those of group A, whereas no difference was found in leptin, TNF-␣, and IL-6 levels ( Figs. 1 and 2 ).
The differences in the clinical and biochemical features between group A and group B are shown in Table 2 .
In univariate analysis, VAI was found to be directly correlated with age of patients ( ϭ 0.408; P ϭ 0.048), tumor volume ( ϭ 0.638; P ϭ 0.001), basal GH ( ϭ 0.622; P ϭ 0.001), nadir of GH ( ϭ 0.534; P ϭ 0.007) and AUC GH ( ϭ 0.603; P ϭ 0.002) during OGTT, IGF-I ULN ( ϭ 0.618; P ϭ 0.001), and AUC Cpeptide ( ϭ 0.715; Ͻ0.001) and inversely correlated with M value ( ϭ Ϫ0.818; P Ͻ 0.001) and DIo ( ϭ Ϫ0.512; P ϭ 0.011). In addition, a strongly significant inverse correlation was found between VAI and adiponectin ( ϭ Ϫ0.766; P Ͻ 0.001), whereas a significant direct correlation was found between VAI and TNF-␣ levels ( ϭ 0.512; P ϭ 0.010). No correlation was found with leptin and IL-6 (Table 3) . In multivariate analysis, AUC GH (B 0.677; P ϭ 0.001) and the family history for diabetes (B 0.386; P ϭ 0.010) were the only variables independently associated with VAI (Table 4) .
Discussion
We analyzed the visceral adipose function, insulin sensitivity and secretion indexes, and adipocytokine levels in a group of newly diagnosed acromegalic patients. Our data show that VAI is independently influenced by GH levels. Patients with high VAI show decreased insulin sensitivity and seem to be less able to compensate the status of IR through an adequate increased insulin secretion. In our hypothesis, the lipotoxicity secondary to the lipolytic action of GH may be clinically expressed by VAI. In fact, in acromegaly, a lipotoxic condition has been described. Freda et al. (4) showed increased im adipose tissue despite a reduction in visceral and sc adipose tissue in 24 adults with active acromegaly compared with healthy subjects, and this finding might be associated with GH-induced IR. Our data showed a strong association between VAI and the rate of peripheral glucose utilization (M value) as in the general population (5). Furthermore, higher VAI showed a strong independent association with both cardiovascular and cerebrovascular events and better predictive capacity for the onset of diabetes events than its individual components (WC, BMI, TG, and HDL) (5, 17) . This index has already been studied in specific populations of patients; in those with genotype 1 chronic hepatitis C and in those with nonalcoholic fatty liver disease, visceral adipose dysfunction identified by a higher VAI score proved to be independently associated with both steatosis and necroinflammatory activity, and fibrosis (18, 19) in women with polycystic ovary syndrome, VAI has proved to be an easy and useful tool for the assessment of cardio- (20) . In our cohort of patients, VAI proved to be strongly correlated with both GH and IGF-I levels and also with tumor volume. As expected, patient age seems to be an additional factor correlated with VAI, and these data seem to be in agreement with those of Fieffe et al. (21) , who showed that age and BMI are significant risk factors of type 2 diabetics.
In this view, older patients and those with higher hormonal levels have more severe visceral adipose dysfunction. Interestingly, the prevalence of high VAI in our acromegalic patients was about twice that of the general population (45.8 vs. 22.78%) (14) . Surprisingly, no difference in MS as a whole and in each of its components, except for systolic hypertension, was reported between the two groups of patients. A possible explanation might lie in the fact that the early stages of metabolic alterations are not highlighted by the classic criteria, whereas VAI seems to be able to show early signs of metabolic risk in patients without overt MS, because the variables are treated as continuous variables and not as dichotomous.
Regarding the increased systolic blood pressure in the group of patients with high VAI, these patients also showed higher GH and IGF-I levels and had a lower degree of insulin sensitivity. In our hypothesis, both the higher insulin levels, known to be associated with increased blood pressure levels in the general population, and higher GH levels, in concert with IGF-I, could have a main impact for the pathogenesis of sodium retention in acromegaly (22, 23) .
Although patients with high VAI were less insulin sensitive, no significant difference in the glucose tolerance categories, except for IGT, was reported between the two groups of patients. This finding supports the hypothesis that VAI shows the early signs of metabolic risk in patients, although a significant reduction in glucose tolerance has not yet occurred. The majority of studies assessed the insulin secretion rate by measurement of insulin levels during OGTT, even though endogenous insulin secretion is assessed more efficiently by the measurement of C-peptide, which is cosecreted with insulin in a one-to-one molar ratio but, unlike insulin, undergoes poor first-pass clearance by the liver. Measurement of C-peptide provides a sensitive, well-accepted, and clinically validated assessment of ␤-cell function (24) , and the gold standard measure of insulin secretion, represented by the measurement of the C-peptide during MMTT (12), has very rarely been used to assess insulin secretion in acromegaly (25) . The higher AUC Cpeptide in patients with high VAI might represent a compensatory mechanism to avoid clear glucose tolerance worsening. For a better evaluation of the ability of ␤-cells to adequately compensate the insulin resistance through increased insulin secretion, we also calculated DIo, which has been shown to predict the development of diabetes in adults (13) . Patients with high VAI, despite higher AUC Cpeptide , showed lower DIo, demonstrating inadequate insulin secretion relative to insulin sensitivity degree.
Our group recently also showed that active acromegaly is strongly associated with visceral adiposity dysfunction, and both somatostatin analogs and surgical therapies are able to improve it, as demonstrated by the significant VAI decrease after 12 months of therapy (26) . However, this study was limited by the lack of data on adipocytokine assessment and evaluation of insulin sensitivity through the gold standard hyperinsulinemic-euglycemic clamp, because insulin sensitivity has been examined using these methods in only a minority of studies and in smaller cohorts of patients (27) (28) (29) (30) . We therefore analyzed cytokine (leptin and adiponectin) and proinflammatory (TNF-␣ and IL-6) activity to establish whether adipose function plays a main role in determining metabolic alterations in acromegalic patients and whether this can be adequately expressed by VAI. In this regard, data regarding adipocytokine levels in active acromegaly available in the literature are controversial, and the evaluation of a possible relationship between GH levels, adipose function, and insulin sensitivity has been poorly investigated.
In our study, patients with high VAI had lower adiponectin levels and consequently less protection against both IR and cardiometabolic risk (31) (32) (33) . A few years ago, a correlation between leptin levels and BMI in acromegalic patients was found but with controversial data (34, 35) . In our opinion, the leptin levels in our study did not show any significant correlation with VAI because leptin should be considered as an indirect index of overall adipose tissue, secreted by adipocytes in proportion to total adipocyte tissue mass, without a correlation with the quality of fat (36) . In fact, a correlation between leptin levels and sc and total adipose tissue has been reported by other authors but without any correlation with GH and IGF-I levels (4) .
A condition of hypoadiponectinemia in acromegaly was demonstrated (37), although Ronchi et al. (38) did not show any significant correlation between adiponectin and insulin sensitivity and resistance indexes. This is probably because insulin homeostasis was assessed by authors using homeostasis model assessment of IR index and quantitative insulin sensitivity check index and not the gold standard clamp (39) .
In our patients, as expected, we found a positive correlation between TNF-␣ and VAI, suggesting a role of TNF-␣ as proinflammatory activity in visceral adipose dysfunction and IR, as already reported in the general population (40) . In our study, we did not find any significant correlation between IL-6 and all parameters evaluated. This datum is not surprising, because although a great deal of evidence implicates IL-6 in the development of IR, there is some conflicting evidence in the literature (41) . The contribution of visceral adipose tissue to circulating levels of IL-6 seems modest (42) , and the existing data in the literature about the role of IL-6 in acromegaly are extremely few (43) .
A weakness of our study could be the limitation of the range of recruited acromegalic patients to a subgroup of patients with lower cardiovascular risk than a totally unselected group of acromegalic patients would have, because in our cohort, we did not have overt diabetic patients, although the data about VAI on acromegalic patients with different degrees of glucose abnormalities, including overt diabetes mellitus, are available in our previous paper (24) .
Another limitation of our study is probably the lack of direct data on body composition, because MRI and computed tomography, to date considered the gold standard for the quantitative evaluation of visceral and sc adipose tissue (44), was not performed, because these two methods are extremely expensive and too complicated for use in routine practice.
We believe that it is important to clarify that the application of VAI as a marker of cardiometabolic risk could have some limitations, mainly relating to the presence of variables in the model that may change over time in relation to lifestyle and/or pharmacological treatment. Therefore, we suggest using VAI as an indicator of altered adipose function associated with cardiometabolic risk but without a predictive future role. Prospective large-scale studies aiming to consider the possible predictive value of VAI regarding cardiovascular risk must necessarily take into account its variation over time.
In conclusion, in active acromegaly, VAI, directly and independently influenced by GH levels and family history 
